Arch Biopartners Inc.
ACHFF
$1.35
$0.010.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -61.57% | 67.73% | -- | -13.43% | -31.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -61.57% | 67.73% | -- | -13.43% | -31.60% |
| Cost of Revenue | -41.51% | 120.92% | 48.43% | -12.93% | -63.76% |
| Gross Profit | -88.14% | -200.70% | -136.30% | 10.95% | 491.70% |
| SG&A Expenses | -67.90% | 23.08% | 6.26% | 128.72% | -61.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.34% | 139.55% | 29.31% | -4.77% | -61.81% |
| Operating Income | 64.12% | -290.51% | -62.30% | -21.78% | 67.96% |
| Income Before Tax | 48.34% | -544.48% | -92.61% | -19.72% | 63.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.34% | -544.48% | -92.61% | -19.72% | 63.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.34% | -544.48% | -92.61% | -19.72% | 63.79% |
| EBIT | 64.12% | -290.51% | -62.30% | -21.78% | 67.96% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 50.00% | -558.62% | -90.74% | -18.26% | 63.92% |
| Normalized Basic EPS | 50.00% | -561.11% | -88.24% | -18.06% | 63.52% |
| EPS Diluted | 50.00% | -558.62% | -90.74% | -18.26% | 63.92% |
| Normalized Diluted EPS | 50.00% | -561.11% | -88.24% | -18.06% | 63.52% |
| Average Basic Shares Outstanding | 3.96% | -2.92% | 0.47% | 1.11% | 0.21% |
| Average Diluted Shares Outstanding | 3.96% | -2.92% | 0.47% | 1.11% | 0.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
